Timpani Capital Management LLC Takes $1.95 Million Position in Omnicell, Inc. (OMCL)
Timpani Capital Management LLC bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 45,224 shares of the company’s stock, valued at approximately $1,949,000. Timpani Capital Management LLC owned about 0.12% of Omnicell at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the business. Ameritas Investment Partners Inc. acquired a new stake in shares of Omnicell in the 1st quarter valued at approximately $125,000. LS Investment Advisors LLC lifted its holdings in shares of Omnicell by 136.3% in the 1st quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock valued at $145,000 after buying an additional 2,060 shares during the period. State of Alaska Department of Revenue lifted its holdings in shares of Omnicell by 3.0% in the 1st quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Omnicell in the 1st quarter valued at approximately $170,000. Finally, Turner Investments LLC acquired a new stake in shares of Omnicell in the 2nd quarter valued at approximately $181,000. Institutional investors own 96.35% of the company’s stock.
Omnicell, Inc. (NASDAQ OMCL) traded up 0.30% during mid-day trading on Friday, hitting $50.00. The stock had a trading volume of 283,654 shares. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $52.70. The company has a 50-day moving average of $49.10 and a 200-day moving average of $42.99. The stock’s market cap is $1.87 billion.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.08 million. During the same period in the prior year, the company posted $0.38 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, analysts anticipate that Omnicell, Inc. will post $1.30 earnings per share for the current fiscal year.
In other Omnicell news, Chairman Randall A. Lipps sold 37,500 shares of the stock in a transaction on Friday, July 28th. The stock was sold at an average price of $46.00, for a total transaction of $1,725,000.00. Following the completion of the transaction, the chairman now directly owns 196,551 shares of the company’s stock, valued at approximately $9,041,346. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gary S. Petersmeyer sold 1,000 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $51.73, for a total value of $51,730.00. The disclosure for this sale can be found here. Insiders sold a total of 202,309 shares of company stock valued at $9,787,437 over the last three months. Corporate insiders own 3.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Timpani Capital Management LLC Takes $1.95 Million Position in Omnicell, Inc. (OMCL)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/10/timpani-capital-management-llc-takes-1-95-million-position-in-omnicell-inc-omcl.html.
Several research firms have recently commented on OMCL. Benchmark Co. raised their price target on Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and issued a $40.00 price target on shares of Omnicell in a report on Sunday, July 30th. Dougherty & Co raised their price target on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Craig Hallum raised their price target on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 28th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $51.57.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.